These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28353185)

  • 21. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents.
    Luo W; Chen D; Wu M; Li Z; Tao Y; Liu Q; Pan Y; Qu W; Yuan Z; Xie S
    J Vet Sci; 2019 Sep; 20(5):e40. PubMed ID: 31565887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T; Suyama H; Doi M; Kuwabara M
    Chemotherapy; 2008; 54(5):386-94. PubMed ID: 18769027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection.
    Trang M; Dudley MN; Bhavnani SM
    Curr Opin Pharmacol; 2017 Oct; 36():107-113. PubMed ID: 29128853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock.
    Varghese JM; Roberts JA; Lipman J
    Crit Care Clin; 2011 Jan; 27(1):19-34. PubMed ID: 21144984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
    Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.
    Gonzalez D; Schmidt S; Derendorf H
    Clin Microbiol Rev; 2013 Apr; 26(2):274-88. PubMed ID: 23554417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial pharmacokinetics and preclinical
    Abbott IJ; Roberts JA; Meletiadis J; Peleg AY
    Expert Rev Anti Infect Ther; 2021 Mar; 19(3):271-295. PubMed ID: 32820686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit.
    Mouton JW; Punt N; Vinks AA
    Clin Ther; 2005 Jun; 27(6):762-72. PubMed ID: 16117983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction.
    Ambrose PG; Bhavnani SM; Cirincione BB; Piedmonte M; Grasela TH
    J Antimicrob Chemother; 2003 Sep; 52(3):435-40. PubMed ID: 12917247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
    Cantón R; Canut A; Morosini MI; Oliver A
    Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():33-40. PubMed ID: 25542050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment.
    DeRyke CA; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):337-44. PubMed ID: 17350206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
    J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
    Ellis JM; Kuti JL; Nicolau DP
    Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
    Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
    Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.